Image Source: Groww
Hemo Organic Ltd has approved raising ₹12.47 crore via convertible warrants to non-promoter investors and increasing its authorized capital to ₹13.45 crore. The move, subject to shareholder approval, supports the company’s growth and complies with SEBI regulations.
Show more
Hemo Organic Limited announced on Thursday, 11th December 2025, that its Board of Directors has approved a significant expansion of its authorized share capital and a preferential issue of convertible warrants to non-promoter investors. The move is aimed at raising fresh capital to support the company's growth plans.
Notable Updates:
-
The authorized share capital has been increased from ₹10 crore to ₹13.45 crore, divided into 1.345 crore equity shares of ₹10 each.
-
The company plans to raise up to ₹12.47 crore by issuing 99.75 lakh convertible warrants to non-promoter investors at ₹12.50 per warrant (face value ₹10, premium ₹2.50).
-
The warrants are convertible into equity shares within 18 months from allotment, with 25% payment upfront and the remaining 75% due at conversion.
-
Investors include Vishwambar Kameshwar Singh, Vacro Enterprises Private Limited, and Qmin Realities Private Limited.
Major Takeaways:
-
The capital increase and fundraising are subject to shareholder approval at the upcoming General Meeting.
-
The issuance aligns with SEBI (LODR) and SEBI (ICDR) regulations, ensuring compliance and transparency.
-
The preferential allotment will help the company strengthen its financial position and fund expansion initiatives.
Important Points:
-
The capital clause in the Memorandum of Association will be altered to reflect the new authorized share capital.
-
All details regarding the issuance, including investor names and payment structure, have been disclosed as per regulatory requirements.
Source: Hemo Organic Limited official announcement, BSE Corporate Announcement.
Stay Ahead – Explore Now!
Godawari Power Gets PGCIL Nod to Supply HT Steel Billets—Eyes ₹150 Cr EBITDA Boost
Advertisement
Advertisement